Celltrion’s active launching process for Truxima, starting to sell in Germany

Celltrion announced on the 18^th that it has started to prepare for an official launch of ‘Truxima,’ the first antibody biosimilar for the treatment of blood cancer, even in Germany after the U.K. and Korea.

Truxima is an antibody biosimilar used to treat various types of blood cancer, like non-Hodgkin’s lymphoma and rheumatoid arthritis; its original pharmaceutical product is an blockbuster dr...